Avanos Medical Inc

Avanos Medical, Inc. operates as a medical technology company. It focuses on delivering clinically medical device solutions to improve patients' quality of life. The firm’s portfolio of product offerings focuses on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avanos Medical Inc reports robust Q4 results and outlines growth strategies

Avanos Medical Inc delivered strong financial performance in Q4 2022, showcasing growth in key product categories and exceeding expectations in OrthogenRx. While facing challenges in certain segments, Avanos is focused on optimizing operations and capitalizing on identified opportunities for growth.

Avanos Medical reports steady Q1 performance amidst strategic transformation

Avanos Medical Inc's Q1 2023 performance was steady, with a focus on operational efficiency and profitability enhancement.
While facing challenges in certain product categories, Avanos is well-positioned to capitalize on growth opportunities through strategic initiatives.
The company's transformation priorities and guidance for the year reflect a proactive approach to navigating market dynamics and driving sustainable value creation.

Avanos Medical Inc reports resilient Q2 performance and outlines growth strategies

Avanos Medical Inc demonstrated resilience in Q2 amidst supply chain challenges and inflation effects.
The company's focus on strategic priorities and shareholder value enhancement initiatives bode well for future growth.
Despite some portfolio challenges, Avanos remains optimistic about mid-single-digit revenue growth in 2024.
Operational efficiency and growth opportunities in key product lines position Avanos for sustained success.

Avanos Medical Inc reports Q3 results, focuses on efficiency and growth

Avanos Medical Inc's Q3 performance reflects mixed results with growth in Digestive Health but decline in Pain Management portfolios.
The company's transformation priorities and cost management efforts aim to drive efficiency and optimize performance.
Despite challenges in certain product segments, Avanos Medical Inc's focus on gross margin improvement and savings targets bode well for future profitability.
Opportunities lie in portfolio transformation, enhanced gross margins, and strategic initiatives like DIros Technology and cost optimization.

Avanos Medical Inc reports stable Q4 earnings amidst growth strategies

Avanos Medical Inc's Q4 performance reflects mixed results with challenges in certain product segments but stable profitability.
The company's strategic priorities aim to drive future growth through portfolio optimization and cost management.
Anticipated revenue growth, focus on M&A, and long-term financial targets position Avanos for sustainable performance and expansion.

Avanos Medical Inc reports solid Q1 performance and growth outlook

Avanos Medical Inc's Q1 2024 performance showed mixed results across portfolios but strong overall financials.
The company's focus on cost management, capital efficiency, and strategic targets bodes well for future growth.
Despite challenges in certain product lines, Avanos remains confident in its strategies and growth trajectory.

Avanos Medical reports resilient Q2 results amidst portfolio growth

Avanos Medical's Q2 performance showcased solid sales figures and growth in key portfolios, despite challenges in certain segments.
The company's strengths lie in maintaining financial guidance, a strong balance sheet, and a strategic focus on transformation initiatives.
While facing challenges in specific product lines, Avanos Medical has opportunities to drive growth through product innovation, strategic partnerships, and capital allocation.
Overall, Avanos Medical remains committed to its transformation journey and delivering value to shareholders through prudent financial management.

Avanos Medical reports Q3 results, focuses on growth strategies

Avanos Medical's Q3 performance reflects a mixed picture with strong Digestive Health growth but challenges in the pain portfolio.
The company's strategic focus on high-margin products, cost management, and growth initiatives positions it for future success.
Despite current challenges, Avanos Medical's pursuit of organic growth, efficient capital allocation, and strategic M&A bode well for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avanos Medical, Inc. is a medical technology company, which engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

ALPHARETTA, Ga. , Nov. 12, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in an analyst-led fireside chat at the Stifel 2024 Healthcare Conference at the Lotte New York Palace in New York on Tuesday, Nov. 19 at approximately 3:35 p.m.

Avanos Medical, Inc. to Present at the Stifel 2024 Healthcare Conference

ALPHARETTA, Ga. , Nov. 11, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) announced today that the Centers for Medicare and Medicaid Services (CMS) has issued its final Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025.

ON-Q* Elastomeric Infusion Pump and ambIT* Disposable Electronic Infusion Pump to Receive Separate Payment Under NOPAIN Act Starting January 1, 2025

ALPHARETTA, Ga. , Nov. 8, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in a fireside chat at the UBS 2024 Healthcare Conference on Tues.

Avanos Medical, Inc. to Present at the UBS Healthcare Conference 2024

Advancement to reduce dislodgement in feeding tube retention systems ALPHARETTA, Ga. , Nov. 5, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced the launch of its newly designed CORGRIP SR Nasogastric/Nasointestinal Tube Retention System, further expanding its comprehensive Enteral Feeding portfolio.

Avanos Medical Launches New CORGRIP® SR

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Avanos Medical (AVNS) Right Now?

Avanos Medical, Inc. AVNS reported third-quarter 2024 adjusted earnings per share (EPS) from continuing operations of 36 cents, up 20% year over year. The bottom line met the Zacks Consensus Estimate.

Avanos Q3 Earnings Meet Estimates, Sales Miss, Gross Margin Contracts

Avanos Medical Inc. (NYSE:AVNS ) Q3 2024 Results Conference Call October 30, 2024 9:00 AM ET Company Participants Scott Galovan - Vice President of Strategy & Corporate Development Gary Blackford - Chairman Michael Greiner - Senior VP, CFO & Chief Transformation Officer Conference Call Participants Kristen Stewart - CL King Danny Stauder - Citizens JMP Operator Good morning, ladies and gentlemen, and welcome to the Avanos Medical, Avanos Third Quarter 2024 Earnings Call. [Operator Instructions] This call is being recorded on Wednesday, October 30, 2024.

Avanos Medical Inc. (AVNS) Q3 2024 Earnings Call Transcript

Avanos Medical (AVNS) came out with quarterly earnings of $0.36 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.30 per share a year ago.

Avanos Medical (AVNS) Q3 Earnings Meet Estimates

ALPHARETTA, Ga. , Oct. 30, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody.

Avanos Medical, Inc. Announces Third Quarter 2024 Results, retirement of CEO

ALPHARETTA, Ga. , Oct. 23, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2024 on Wednesday, Oct. 30 at 9 a.m.

Avanos Medical, Inc. to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

Avanos Medical (AVNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Avanos Medical (AVNS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Should Value Investors Buy Avanos Medical (AVNS) Stock?

AVNS's strong product line and focus on R&D raise optimism about the stock.

Reasons to Add Avanos Medical Stock in Your Portfolio Now

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Avanos Medical (AVNS) is a Top Momentum Stock for the Long-Term

AVNS' GAME READY announces a paid partnership with NFL defensive end and San Francisco 49ers star, Nick Bosa.

Avanos Medical Stock May Gain From Brand Partnership With NFL

ALPHARETTA, Ga. , Sept. 9, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, senior vice president, chief financial officer, and chief transformation officer will participate in a fireside chat at CL King's virtual 22nd Annual Best Ideas Conference 2024 on Mon.

Avanos Medical, Inc. to Present at the 2024 CL King Annual Best Ideas Conference

Is Avanos Medical (AVNS) Stock Undervalued Right Now?

Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.

Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts

Avanos Medical, Inc. (NYSE:AVNS ) Q2 2024 Earnings Conference Call July 31, 2024 9:00 AM ET Company Participants Scott Galovan - SVP, Strategy & Corporate Development Joe Woody - Chief Executive Officer Michael Greiner - SVP, Chief Financial Officer & Chief Transformation Officer Conference Call Participants Kristen Stewart - CL King Rick Wise - Stifel Daniel Stauder - Citizens JMP Operator Good morning, ladies and gentlemen, and welcome to the Avanos Medical Q2 2024 Earnings Call. At this time, all lines are in a listen-only mode.

Avanos Medical, Inc. (AVNS) Q2 2024 Earnings Call Transcript

Avanos Medical (AVNS) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.24 per share a year ago.

Avanos Medical (AVNS) Beats Q2 Earnings and Revenue Estimates

ALPHARETTA, Ga. , July 31, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2024 financial results.

Avanos Medical, Inc. Announces Second Quarter 2024 Results

Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.

Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

ALPHARETTA, Ga. , July 24, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2024 on Wednesday, July 31 at 9 a.m.

Avanos Medical, Inc. to Webcast Conference Call Discussing Second Quarter 2024 Financial Results

ALPHARETTA, Ga. , July 1, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors.

Avanos Medical, Inc. Appoints Indrani Franchini to Board of Directors

ALPHARETTA, Ga. , May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain.

News for Avanos Medical Inc Stock (AVNS)